Tapewire

Nasdaq · USD

TNDM

TANDEM DIABETES CARE INC

Export transactions ↓
Tapewire entity
4682
SEC CIK
0001438133
Parsed reports
672

Last 12 months

Inside the activity.

0 purchase rows · 2 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202500
Dec 202500
Jan 202600
Feb 202600
Mar 202602
Apr 202600
May 202600
Jun 202600
Jul 202600
Aug 202600
Sep 202600
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
February 25, 2025 Filed Feb 27, 2025 22:15 UTC
Gasser Elizabeth AnneEVP, Chief Strategy Officer
Tax withholdingCommon Stock 739 $33.34 $24,638.26
Disclosure

SEC source: 0001438133-25-000038 · wk-form4_1740694524.xml · nonDerivative · entry 2

Gasser Elizabeth Anne · CIK 0001866283 · EVP, Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,509

F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of performance stock units (PSU). No shares were sold.

Read SEC document
February 25, 2025 Filed Feb 27, 2025 22:15 UTC
Gasser Elizabeth AnneEVP, Chief Strategy Officer
Exercise / conversionCommon Stock 1,380 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000038 · wk-form4_1740694524.xml · nonDerivative · entry 1

Gasser Elizabeth Anne · CIK 0001866283 · EVP, Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,248

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 25, 2025 Filed Feb 27, 2025 22:15 UTC
Vosseller LeighEVP & CHIEF FINANCIAL OFFICER
Exercise / conversionPerformance Stock Unit · Derivative 5,523 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000039 · wk-form4_1740694537.xml · derivative · entry 7

Vosseller Leigh · CIK 0001726322 · EVP & CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,523 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · security: Awarded on May 25, 2022 pursuant to the 2013 Plan.

F4 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the Company common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2024 (the Measurement Date). The number of shares issued may range from 0% to 200% of the base grant amount, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest.

F4 · derivative.exercise_date: Each PSU represents a contingent right to receive one share of the Company common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2024 (the Measurement Date). The number of shares issued may range from 0% to 200% of the base grant amount, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest.

F4 · derivative.expiration_date: Each PSU represents a contingent right to receive one share of the Company common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2024 (the Measurement Date). The number of shares issued may range from 0% to 200% of the base grant amount, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest.

Read SEC document
February 25, 2025 Filed Feb 27, 2025 22:15 UTC
Vosseller LeighEVP & CHIEF FINANCIAL OFFICER
Exercise / conversionPerformance Stock Unit · Derivative 1,380 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000039 · wk-form4_1740694537.xml · derivative · entry 6

Vosseller Leigh · CIK 0001726322 · EVP & CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,380 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: Awarded on May 18, 2021 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the 2013 Plan).

F4 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the Company common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2024 (the Measurement Date). The number of shares issued may range from 0% to 200% of the base grant amount, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest.

F4 · derivative.exercise_date: Each PSU represents a contingent right to receive one share of the Company common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2024 (the Measurement Date). The number of shares issued may range from 0% to 200% of the base grant amount, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest.

F4 · derivative.expiration_date: Each PSU represents a contingent right to receive one share of the Company common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2024 (the Measurement Date). The number of shares issued may range from 0% to 200% of the base grant amount, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest.

Read SEC document
February 25, 2025 Filed Feb 27, 2025 22:15 UTC
Vosseller LeighEVP & CHIEF FINANCIAL OFFICER
Tax withholdingCommon Stock 2,027 $33.34 $67,580.18
Disclosure

SEC source: 0001438133-25-000039 · wk-form4_1740694537.xml · nonDerivative · entry 4

Vosseller Leigh · CIK 0001726322 · EVP & CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,225

F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of performance stock units (PSU). No shares were sold.

Read SEC document
February 25, 2025 Filed Feb 27, 2025 22:15 UTC
Vosseller LeighEVP & CHIEF FINANCIAL OFFICER
Exercise / conversionCommon Stock 5,523 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000039 · wk-form4_1740694537.xml · nonDerivative · entry 3

Vosseller Leigh · CIK 0001726322 · EVP & CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,252

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 25, 2025 Filed Feb 27, 2025 22:15 UTC
Vosseller LeighEVP & CHIEF FINANCIAL OFFICER
Tax withholdingCommon Stock 494 $33.34 $16,469.96
Disclosure

SEC source: 0001438133-25-000039 · wk-form4_1740694537.xml · nonDerivative · entry 2

Vosseller Leigh · CIK 0001726322 · EVP & CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,729

F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of performance stock units (PSU). No shares were sold.

Read SEC document
February 25, 2025 Filed Feb 27, 2025 22:15 UTC
Vosseller LeighEVP & CHIEF FINANCIAL OFFICER
Exercise / conversionCommon Stock 1,380 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000039 · wk-form4_1740694537.xml · nonDerivative · entry 1

Vosseller Leigh · CIK 0001726322 · EVP & CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,223

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 25, 2025 Filed Feb 27, 2025 22:15 UTC
Morrison SusanEVP & Chief Admin. Officer
Exercise / conversionPerformance Stock Unit · Derivative 5,523 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000040 · wk-form4_1740694547.xml · derivative · entry 6

Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,523 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · security: Awarded on May 25, 2022 pursuant to the 2013 Plan.

F3 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the Company common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2024 (the Measurement Date). The number of shares issued may range from 0% to 200% of the base grant amount, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest.

F3 · derivative.exercise_date: Each PSU represents a contingent right to receive one share of the Company common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2024 (the Measurement Date). The number of shares issued may range from 0% to 200% of the base grant amount, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest.

F3 · derivative.expiration_date: Each PSU represents a contingent right to receive one share of the Company common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2024 (the Measurement Date). The number of shares issued may range from 0% to 200% of the base grant amount, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest.

Read SEC document
February 25, 2025 Filed Feb 27, 2025 22:15 UTC
Morrison SusanEVP & Chief Admin. Officer
Exercise / conversionPerformance Stock Unit · Derivative 1,380 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000040 · wk-form4_1740694547.xml · derivative · entry 5

Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,380 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Awarded on May 18, 2021 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the 2013 Plan).

F3 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the Company common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2024 (the Measurement Date). The number of shares issued may range from 0% to 200% of the base grant amount, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest.

F3 · derivative.exercise_date: Each PSU represents a contingent right to receive one share of the Company common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2024 (the Measurement Date). The number of shares issued may range from 0% to 200% of the base grant amount, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest.

F3 · derivative.expiration_date: Each PSU represents a contingent right to receive one share of the Company common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2024 (the Measurement Date). The number of shares issued may range from 0% to 200% of the base grant amount, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest.

Read SEC document
February 25, 2025 Filed Feb 27, 2025 22:15 UTC
Morrison SusanEVP & Chief Admin. Officer
Tax withholdingCommon Stock 1,632 $33.34 $54,410.88
Disclosure

SEC source: 0001438133-25-000040 · wk-form4_1740694547.xml · nonDerivative · entry 4

Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,189

F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of performance stock units (PSU). No shares were sold.

Read SEC document
February 25, 2025 Filed Feb 27, 2025 22:15 UTC
Morrison SusanEVP & Chief Admin. Officer
Exercise / conversionCommon Stock 5,523 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000040 · wk-form4_1740694547.xml · nonDerivative · entry 3

Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,821

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 25, 2025 Filed Feb 27, 2025 22:15 UTC
Morrison SusanEVP & Chief Admin. Officer
Tax withholdingCommon Stock 395 $33.34 $13,169.30
Disclosure

SEC source: 0001438133-25-000040 · wk-form4_1740694547.xml · nonDerivative · entry 2

Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,298

F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of performance stock units (PSU). No shares were sold.

Read SEC document
February 25, 2025 Filed Feb 27, 2025 22:15 UTC
Morrison SusanEVP & Chief Admin. Officer
Exercise / conversionCommon Stock 1,380 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000040 · wk-form4_1740694547.xml · nonDerivative · entry 1

Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,693

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 25, 2025 Filed Feb 27, 2025 22:15 UTC
Sheridan John FDirector · PRESIDENT & CEO
Exercise / conversionPerformance Stock Unit · Derivative 26,047 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000037 · wk-form4_1740694513.xml · derivative · entry 6

Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 26,047 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · security: Awarded on May 25, 2022 pursuant to the 2013 Plan.

F3 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the Company common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2024 (the Measurement Date). The number of shares issued may range from 0% to 200% of the base grant amount, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest.

F3 · derivative.exercise_date: Each PSU represents a contingent right to receive one share of the Company common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2024 (the Measurement Date). The number of shares issued may range from 0% to 200% of the base grant amount, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest.

F3 · derivative.expiration_date: Each PSU represents a contingent right to receive one share of the Company common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2024 (the Measurement Date). The number of shares issued may range from 0% to 200% of the base grant amount, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest.

Read SEC document
February 25, 2025 Filed Feb 27, 2025 22:15 UTC
Sheridan John FDirector · PRESIDENT & CEO
Exercise / conversionPerformance Stock Unit · Derivative 6,732 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000037 · wk-form4_1740694513.xml · derivative · entry 5

Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,732 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Awarded on May 18, 2021 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the 2013 Plan).

F3 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the Company common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2024 (the Measurement Date). The number of shares issued may range from 0% to 200% of the base grant amount, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest.

F3 · derivative.exercise_date: Each PSU represents a contingent right to receive one share of the Company common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2024 (the Measurement Date). The number of shares issued may range from 0% to 200% of the base grant amount, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest.

F3 · derivative.expiration_date: Each PSU represents a contingent right to receive one share of the Company common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2024 (the Measurement Date). The number of shares issued may range from 0% to 200% of the base grant amount, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest.

Read SEC document
February 25, 2025 Filed Feb 27, 2025 22:15 UTC
Sheridan John FDirector · PRESIDENT & CEO
Tax withholdingCommon Stock 10,008 $33.34 $333,666.72
Disclosure

SEC source: 0001438133-25-000037 · wk-form4_1740694513.xml · nonDerivative · entry 4

Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,009

F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of performance stock units (PSU). No shares were sold.

Read SEC document
February 25, 2025 Filed Feb 27, 2025 22:15 UTC
Sheridan John FDirector · PRESIDENT & CEO
Exercise / conversionCommon Stock 26,047 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000037 · wk-form4_1740694513.xml · nonDerivative · entry 3

Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 89,017

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 25, 2025 Filed Feb 27, 2025 22:15 UTC
Sheridan John FDirector · PRESIDENT & CEO
Tax withholdingCommon Stock 3,419 $33.34 $113,989.46
Disclosure

SEC source: 0001438133-25-000037 · wk-form4_1740694513.xml · nonDerivative · entry 2

Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,970

F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of performance stock units (PSU). No shares were sold.

Read SEC document
February 25, 2025 Filed Feb 27, 2025 22:15 UTC
Sheridan John FDirector · PRESIDENT & CEO
Exercise / conversionCommon Stock 6,732 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000037 · wk-form4_1740694513.xml · nonDerivative · entry 1

Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,389

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 18, 2025 Filed Feb 20, 2025 22:07 UTC
Gasser Elizabeth AnneEVP, Chief Strategy Officer
Exercise / conversionRestricted Stock Unit · Derivative 1,504 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000020 · wk-form4_1740089263.xml · derivative · entry 10

Gasser Elizabeth Anne · CIK 0001866283 · EVP, Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,515

Underlying: Common Stock · 1,504 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · security: Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).

F9 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

F10 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

F10 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Read SEC document
February 18, 2025 Filed Feb 20, 2025 22:07 UTC
Gasser Elizabeth AnneEVP, Chief Strategy Officer
Exercise / conversionRestricted Stock Unit · Derivative 474 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000020 · wk-form4_1740089263.xml · derivative · entry 9

Gasser Elizabeth Anne · CIK 0001866283 · EVP, Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 474

Underlying: Common Stock · 474 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · security: Awarded on May 25, 2022 pursuant to the 2013 Plan.

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan.

F7 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2023, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

F7 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2023, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Read SEC document
February 18, 2025 Filed Feb 20, 2025 22:07 UTC
Gasser Elizabeth AnneEVP, Chief Strategy Officer
Exercise / conversionRestricted Stock Unit · Derivative 163 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000020 · wk-form4_1740089263.xml · derivative · entry 8

Gasser Elizabeth Anne · CIK 0001866283 · EVP, Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 162

Underlying: Common Stock · 163 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: Awarded on May 18, 2021 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the 2013 Plan).

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan.

F5 · derivative.exercise_date: RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 5/15/2022, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter.

F5 · derivative.expiration_date: RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 5/15/2022, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter.

Read SEC document
February 18, 2025 Filed Feb 20, 2025 22:07 UTC
Gasser Elizabeth AnneEVP, Chief Strategy Officer
Tax withholdingCommon Stock 886 $33.47 $29,654.42
Disclosure

SEC source: 0001438133-25-000020 · wk-form4_1740089263.xml · nonDerivative · entry 6

Gasser Elizabeth Anne · CIK 0001866283 · EVP, Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,868

F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
February 18, 2025 Filed Feb 20, 2025 22:07 UTC
Gasser Elizabeth AnneEVP, Chief Strategy Officer
Exercise / conversionCommon Stock 1,504 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000020 · wk-form4_1740089263.xml · nonDerivative · entry 5

Gasser Elizabeth Anne · CIK 0001866283 · EVP, Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,754

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 18, 2025 Filed Feb 20, 2025 22:07 UTC
Gasser Elizabeth AnneEVP, Chief Strategy Officer
Tax withholdingCommon Stock 279 $33.47 $9,338.13
Disclosure

SEC source: 0001438133-25-000020 · wk-form4_1740089263.xml · nonDerivative · entry 4

Gasser Elizabeth Anne · CIK 0001866283 · EVP, Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,250

F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
February 18, 2025 Filed Feb 20, 2025 22:07 UTC
Gasser Elizabeth AnneEVP, Chief Strategy Officer
Exercise / conversionCommon Stock 474 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000020 · wk-form4_1740089263.xml · nonDerivative · entry 3

Gasser Elizabeth Anne · CIK 0001866283 · EVP, Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,529

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 18, 2025 Filed Feb 20, 2025 22:07 UTC
Gasser Elizabeth AnneEVP, Chief Strategy Officer
Tax withholdingCommon Stock 96 $33.47 $3,213.12
Disclosure

SEC source: 0001438133-25-000020 · wk-form4_1740089263.xml · nonDerivative · entry 2

Gasser Elizabeth Anne · CIK 0001866283 · EVP, Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,055

F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
February 18, 2025 Filed Feb 20, 2025 22:07 UTC
Gasser Elizabeth AnneEVP, Chief Strategy Officer
Exercise / conversionCommon Stock 163 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000020 · wk-form4_1740089263.xml · nonDerivative · entry 1

Gasser Elizabeth Anne · CIK 0001866283 · EVP, Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,151

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 18, 2025 Filed Feb 20, 2025 22:07 UTC
Vosseller LeighEVP & CHIEF FINANCIAL OFFICER
Exercise / conversionRestricted Stock Unit · Derivative 1,504 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000016 · wk-form4_1740089218.xml · derivative · entry 10

Vosseller Leigh · CIK 0001726322 · EVP & CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,515

Underlying: Common Stock · 1,504 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · security: Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).

F9 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

F10 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

F10 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Read SEC document
February 18, 2025 Filed Feb 20, 2025 22:07 UTC
Vosseller LeighEVP & CHIEF FINANCIAL OFFICER
Exercise / conversionRestricted Stock Unit · Derivative 474 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000016 · wk-form4_1740089218.xml · derivative · entry 9

Vosseller Leigh · CIK 0001726322 · EVP & CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 474

Underlying: Common Stock · 474 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · security: Awarded on May 25, 2022 pursuant to the 2013 Plan.

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan.

F7 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2023, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

F7 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2023, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Read SEC document
February 18, 2025 Filed Feb 20, 2025 22:07 UTC
Vosseller LeighEVP & CHIEF FINANCIAL OFFICER
Exercise / conversionRestricted Stock Unit · Derivative 163 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000016 · wk-form4_1740089218.xml · derivative · entry 8

Vosseller Leigh · CIK 0001726322 · EVP & CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 162

Underlying: Common Stock · 163 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: Awarded on May 18, 2021 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the 2013 Plan).

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan.

F5 · derivative.exercise_date: RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 5/15/2022, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter.

F5 · derivative.expiration_date: RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 5/15/2022, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter.

Read SEC document
February 18, 2025 Filed Feb 20, 2025 22:07 UTC
Vosseller LeighEVP & CHIEF FINANCIAL OFFICER
Tax withholdingCommon Stock 618 $33.47 $20,684.46
Disclosure

SEC source: 0001438133-25-000016 · wk-form4_1740089218.xml · nonDerivative · entry 6

Vosseller Leigh · CIK 0001726322 · EVP & CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,843

F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
February 18, 2025 Filed Feb 20, 2025 22:07 UTC
Vosseller LeighEVP & CHIEF FINANCIAL OFFICER
Exercise / conversionCommon Stock 1,504 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000016 · wk-form4_1740089218.xml · nonDerivative · entry 5

Vosseller Leigh · CIK 0001726322 · EVP & CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,461

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 18, 2025 Filed Feb 20, 2025 22:07 UTC
Vosseller LeighEVP & CHIEF FINANCIAL OFFICER
Tax withholdingCommon Stock 195 $33.47 $6,526.65
Disclosure

SEC source: 0001438133-25-000016 · wk-form4_1740089218.xml · nonDerivative · entry 4

Vosseller Leigh · CIK 0001726322 · EVP & CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,957

F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
February 18, 2025 Filed Feb 20, 2025 22:07 UTC
Vosseller LeighEVP & CHIEF FINANCIAL OFFICER
Exercise / conversionCommon Stock 474 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000016 · wk-form4_1740089218.xml · nonDerivative · entry 3

Vosseller Leigh · CIK 0001726322 · EVP & CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,152

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 18, 2025 Filed Feb 20, 2025 22:07 UTC
Vosseller LeighEVP & CHIEF FINANCIAL OFFICER
Tax withholdingCommon Stock 67 $33.47 $2,242.49
Disclosure

SEC source: 0001438133-25-000016 · wk-form4_1740089218.xml · nonDerivative · entry 2

Vosseller Leigh · CIK 0001726322 · EVP & CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,678

F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
February 18, 2025 Filed Feb 20, 2025 22:07 UTC
Vosseller LeighEVP & CHIEF FINANCIAL OFFICER
Exercise / conversionCommon Stock 163 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000016 · wk-form4_1740089218.xml · nonDerivative · entry 1

Vosseller Leigh · CIK 0001726322 · EVP & CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,745

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 18, 2025 Filed Feb 20, 2025 22:07 UTC
Hansen Shannon MarieEVP & Chief Legal Officer
Exercise / conversionRestricted Stock Unit · Derivative 1,438 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000019 · wk-form4_1740089252.xml · derivative · entry 7

Hansen Shannon Marie · CIK 0001908267 · EVP & Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,185

Underlying: Common Stock · 1,438 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · security: Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).

F7 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

F8 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

F8 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Read SEC document
February 18, 2025 Filed Feb 20, 2025 22:07 UTC
Hansen Shannon MarieEVP & Chief Legal Officer
Exercise / conversionRestricted Stock Unit · Derivative 531 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000019 · wk-form4_1740089252.xml · derivative · entry 6

Hansen Shannon Marie · CIK 0001908267 · EVP & Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,123

Underlying: Common Stock · 531 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: Awarded on February 15, 2022 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the 2013 Plan).

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan.

F5 · derivative.exercise_date: RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 2/15/2023, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter.

F5 · derivative.expiration_date: RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 2/15/2023, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter.

Read SEC document
February 18, 2025 Filed Feb 20, 2025 22:07 UTC
Hansen Shannon MarieEVP & Chief Legal Officer
Tax withholdingCommon Stock 591 $33.47 $19,780.77
Disclosure

SEC source: 0001438133-25-000019 · wk-form4_1740089252.xml · nonDerivative · entry 4

Hansen Shannon Marie · CIK 0001908267 · EVP & Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,662

F1 · shares: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
February 18, 2025 Filed Feb 20, 2025 22:07 UTC
Hansen Shannon MarieEVP & Chief Legal Officer
Exercise / conversionCommon Stock 1,438 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000019 · wk-form4_1740089252.xml · nonDerivative · entry 3

Hansen Shannon Marie · CIK 0001908267 · EVP & Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,253

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 18, 2025 Filed Feb 20, 2025 22:07 UTC
Hansen Shannon MarieEVP & Chief Legal Officer
Tax withholdingCommon Stock 219 $33.47 $7,329.93
Disclosure

SEC source: 0001438133-25-000019 · wk-form4_1740089252.xml · nonDerivative · entry 2

Hansen Shannon Marie · CIK 0001908267 · EVP & Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,815

F1 · shares: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
February 18, 2025 Filed Feb 20, 2025 22:07 UTC
Hansen Shannon MarieEVP & Chief Legal Officer
Exercise / conversionCommon Stock 531 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000019 · wk-form4_1740089252.xml · nonDerivative · entry 1

Hansen Shannon Marie · CIK 0001908267 · EVP & Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,034

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 18, 2025 Filed Feb 20, 2025 22:07 UTC
Morrison SusanEVP & Chief Admin. Officer
Exercise / conversionRestricted Stock Unit · Derivative 1,504 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000018 · wk-form4_1740089240.xml · derivative · entry 9

Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,515

Underlying: Common Stock · 1,504 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · security: Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).

F8 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

F9 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

F9 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Read SEC document
February 18, 2025 Filed Feb 20, 2025 22:07 UTC
Morrison SusanEVP & Chief Admin. Officer
Exercise / conversionRestricted Stock Unit · Derivative 474 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000018 · wk-form4_1740089240.xml · derivative · entry 8

Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 474

Underlying: Common Stock · 474 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · security: Awarded on May 25, 2022 pursuant to the 2013 Plan.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan.

F6 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2023, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

F6 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2023, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Read SEC document
February 18, 2025 Filed Feb 20, 2025 22:07 UTC
Morrison SusanEVP & Chief Admin. Officer
Exercise / conversionRestricted Stock Unit · Derivative 163 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000018 · wk-form4_1740089240.xml · derivative · entry 7

Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 162

Underlying: Common Stock · 163 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Awarded on May 18, 2021 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the 2013 Plan).

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan.

F4 · derivative.exercise_date: RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 5/15/2022, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter.

F4 · derivative.expiration_date: RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 5/15/2022, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter.

Read SEC document
February 18, 2025 Filed Feb 20, 2025 22:07 UTC
Morrison SusanEVP & Chief Admin. Officer
Tax withholdingCommon Stock 510 $33.47 $17,069.70
Disclosure

SEC source: 0001438133-25-000018 · wk-form4_1740089240.xml · nonDerivative · entry 6

Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,313

F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
February 18, 2025 Filed Feb 20, 2025 22:07 UTC
Morrison SusanEVP & Chief Admin. Officer
Exercise / conversionCommon Stock 1,504 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000018 · wk-form4_1740089240.xml · nonDerivative · entry 5

Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,823

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 18, 2025 Filed Feb 20, 2025 22:07 UTC
Morrison SusanEVP & Chief Admin. Officer
Tax withholdingCommon Stock 161 $33.47 $5,388.67
Disclosure

SEC source: 0001438133-25-000018 · wk-form4_1740089240.xml · nonDerivative · entry 4

Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,319

F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.